CN115210237A - 一种二氢嘧啶类化合物、其制备方法及其应用 - Google Patents

一种二氢嘧啶类化合物、其制备方法及其应用 Download PDF

Info

Publication number
CN115210237A
CN115210237A CN202280001636.0A CN202280001636A CN115210237A CN 115210237 A CN115210237 A CN 115210237A CN 202280001636 A CN202280001636 A CN 202280001636A CN 115210237 A CN115210237 A CN 115210237A
Authority
CN
China
Prior art keywords
alkyl
methyl
compound
substituted
bicyclo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202280001636.0A
Other languages
English (en)
Other versions
CN115210237B (zh
Inventor
唐国志
马大为
陈军利
黄孟炜
张金良
张国亮
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Weishen Pharmaceutical Co ltd
Original Assignee
Shanghai Weishen Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Weishen Pharmaceutical Co ltd filed Critical Shanghai Weishen Pharmaceutical Co ltd
Publication of CN115210237A publication Critical patent/CN115210237A/zh
Application granted granted Critical
Publication of CN115210237B publication Critical patent/CN115210237B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明公开了一种二氢嘧啶类化合物、其制备方法及其应用。具体的本发明公开了如式I’所示的二氢嘧啶类化合物或其药学上可接受的盐,以及含有该类化合物的组合物以及该类化合物用于制备治疗与预防HBV感染有关的药物。本申请中的二氢嘧啶类化合物能有效抑制在HepG2.2.15细胞中HBV(乙肝病毒)的活性且对肝癌细胞毒性小。

Description

PCT国内申请,说明书已公开。

Claims (16)

  1. PCT国内申请,权利要求书已公开。
CN202280001636.0A 2021-02-09 2022-02-08 一种二氢嘧啶类化合物、其制备方法及其应用 Active CN115210237B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2021101826790 2021-02-09
CN202110182679 2021-02-09
CN202110773266X 2021-07-08
CN202110773266 2021-07-08
PCT/CN2022/075494 WO2022171072A1 (zh) 2021-02-09 2022-02-08 一种二氢嘧啶类化合物、其制备方法及其应用

Publications (2)

Publication Number Publication Date
CN115210237A true CN115210237A (zh) 2022-10-18
CN115210237B CN115210237B (zh) 2023-11-14

Family

ID=82780689

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202210117708.XA Pending CN114907355A (zh) 2021-02-09 2022-02-08 一种二氢嘧啶类化合物、其制备方法及其应用
CN202280001636.0A Active CN115210237B (zh) 2021-02-09 2022-02-08 一种二氢嘧啶类化合物、其制备方法及其应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202210117708.XA Pending CN114907355A (zh) 2021-02-09 2022-02-08 一种二氢嘧啶类化合物、其制备方法及其应用

Country Status (4)

Country Link
US (1) US20240166649A1 (zh)
EP (1) EP4293022A1 (zh)
CN (2) CN114907355A (zh)
WO (1) WO2022171072A1 (zh)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106061978A (zh) * 2014-03-07 2016-10-26 豪夫迈·罗氏有限公司 用于治疗和预防乙型肝炎病毒感染的新的6‑稠合的杂芳基二氢嘧啶
CN109678859A (zh) * 2017-10-18 2019-04-26 广东东阳光药业有限公司 二氢嘧啶类化合物及其在药物中的应用
WO2020125729A1 (en) * 2018-12-20 2020-06-25 Janssen Pharmaceutica Nv Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis b infections
WO2020125730A1 (en) * 2018-12-20 2020-06-25 Janssen Pharmaceutica Nv Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis b infections

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020135439A1 (zh) * 2018-12-25 2020-07-02 广东东阳光药业有限公司 氘代二氢嘧啶类化合物及其在药物中的应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106061978A (zh) * 2014-03-07 2016-10-26 豪夫迈·罗氏有限公司 用于治疗和预防乙型肝炎病毒感染的新的6‑稠合的杂芳基二氢嘧啶
CN109678859A (zh) * 2017-10-18 2019-04-26 广东东阳光药业有限公司 二氢嘧啶类化合物及其在药物中的应用
WO2020125729A1 (en) * 2018-12-20 2020-06-25 Janssen Pharmaceutica Nv Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis b infections
WO2020125730A1 (en) * 2018-12-20 2020-06-25 Janssen Pharmaceutica Nv Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis b infections

Also Published As

Publication number Publication date
CN115210237B (zh) 2023-11-14
CN114907355A (zh) 2022-08-16
US20240166649A1 (en) 2024-05-23
WO2022171072A1 (zh) 2022-08-18
EP4293022A1 (en) 2023-12-20

Similar Documents

Publication Publication Date Title
JP6326533B2 (ja) Bruton型チロシンキナーゼ阻害薬
JP2023506532A (ja) Kras突然変異型タンパク質阻害剤
JP7046940B2 (ja) 神経栄養因子チロシンキナーゼ受容体阻害剤として用いられるアミノピラゾロピリミジン化合物
EP3921320B1 (en) Imidazo [2, 1-f] [1, 2, 4] triazin-4-amine derivatives as tlr7 agonist
EP2334683B1 (en) Saturated bicyclic heterocyclic derivatives as smo antagonists
JP2023527242A (ja) Axl阻害剤であるピリミジン系化合物
CN112341377A (zh) 一种杂环类化合物及其应用
CN115210237B (zh) 一种二氢嘧啶类化合物、其制备方法及其应用
JP2024509243A (ja) 複素環置換ケトン類誘導体、その組成物および医薬における使用
CN116888118A (zh) 苯基二氢嘧啶类化合物及其应用
CN115003673B (zh) 一种二氢嘧啶类化合物、其制备方法及应用
WO2021194982A1 (en) Potent and selective irreversible inhibitors of irak1
WO2023179773A1 (en) Bicyclic heterocycles and their ligands for targeted delivery of therapeutic agents
WO2024073559A1 (en) Bicyclic compounds
EA046488B1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗО[2,1-f][1,2,4]ТРИАЗИН-4-АМИНА В КАЧЕСТВЕ АГОНИСТОВ TLR7
TW202330546A (zh) 具有irak4抑制活性的化合物,包含其的藥物組合物,及其應用
TW202409011A (zh) 人類呼吸道融合病毒及間質肺病毒抑制劑
JP2020512331A (ja) 抗c型肝炎ウイルス感染のためのケイ素含有化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
EE01 Entry into force of recordation of patent licensing contract
EE01 Entry into force of recordation of patent licensing contract

Application publication date: 20221018

Assignee: Suzhou Shentuo Pharmaceutical Technology Co.,Ltd.

Assignor: Shanghai Weishen Pharmaceutical Co.,Ltd.

Contract record no.: X2023990000874

Denomination of invention: A dihydropyrimidine compound, its preparation method and application

License type: Common License

Record date: 20231016

GR01 Patent grant
GR01 Patent grant